OncoMatch

OncoMatch/Clinical Trials/NCT05211570

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Is NCT05211570 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including AB8939 and Venetoclax for acute myeloid leukemia refractory.

Phase 1/2RecruitingAB ScienceNCT05211570Data as of May 2026

Treatment: AB8939 · Venetoclax — The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 3 prior lines
Min 2 prior lines

Cannot have received: hematopoietic stem cell transplantation

Exception: HSCT within 100 days prior to the first administration of AB8939

Patients with HSCT within 100 days prior to the first administration of AB8939

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • MD Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify